Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Significant Increase in Short Interest

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the target of a significant growth in short interest in November. As of November 30th, there was short interest totalling 115,000 shares, a growth of 142.6% from the November 15th total of 47,400 shares. Based on an average daily volume of 653,700 shares, the short-interest ratio is currently 0.2 days. Currently, 0.2% of the shares of the stock are short sold.

Eterna Therapeutics Stock Down 1.8 %

Shares of Eterna Therapeutics stock traded down $0.01 during mid-day trading on Wednesday, reaching $0.32. 265,434 shares of the stock traded hands, compared to its average volume of 185,853. The business has a 50-day moving average of $0.83 and a 200 day moving average of $1.43. The stock has a market capitalization of $1.75 million, a PE ratio of -0.04 and a beta of 4.19. Eterna Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $2.63.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.